-
General psychiatry, still in no-man's land after all these years Br. J. Psychiatry (IF 10.5) Pub Date : 2023-11-29 Martin Deahl
Mental health services have changed beyond recognition in my 38-year career. In this editorial I reflect on those changes and highlight the issues that undermine patient care and damage staff morale. In particular, modern mental health services have undermined the therapeutic relationship, the bedrock underpinning all psychiatric treatment.
-
Association of hippocampal subfield volumes with prevalence, course and incidence of depressive symptoms: The Maastricht Study Br. J. Psychiatry (IF 10.5) Pub Date : 2023-11-23 Jennifer Monereo-Sánchez, Jacobus F. A. Jansen, Martin P. J. van Boxtel, Walter H. Backes, Sebastian Köhler, Coen D. A. Stehouwer, David E. J. Linden, Miranda T. Schram
Background Late-life depression has been associated with volume changes of the hippocampus. However, little is known about its association with specific hippocampal subfields over time.Aims We investigated whether hippocampal subfield volumes were associated with prevalence, course and incidence of depressive symptoms.Method We extracted 12 hippocampal subfield volumes per hemisphere with FreeSurfer
-
How to classify antipsychotics: time to ditch dichotomies? Br. J. Psychiatry (IF 10.5) Pub Date : 2023-11-14 Robert A. McCutcheon, Alistair Cannon, Sita Parmer, Oliver D. Howes
The dichotomies of ‘typical/atypical’ or ‘first/second generation’ have been employed for several decades to classify antipsychotics, but justification for their use is not clear. In the current analysis we argue that this classification is flawed from both clinical and pharmacological perspectives. We then consider what approach should ideally be employed in both clinical and research settings.
-
Algorithmic fairness in precision psychiatry: analysis of prediction models in individuals at clinical high risk for psychosis Br. J. Psychiatry (IF 10.5) Pub Date : 2023-11-08 Derya Şahin, Lana Kambeitz-Ilankovic, Stephen Wood, Dominic Dwyer, Rachel Upthegrove, Raimo Salokangas, Stefan Borgwardt, Paolo Brambilla, Eva Meisenzahl, Stephan Ruhrmann, Frauke Schultze-Lutter, Rebekka Lencer, Alessandro Bertolino, Christos Pantelis, Nikolaos Koutsouleris, Joseph Kambeitz, for the PRONIA Study Group
Background Computational models offer promising potential for personalised treatment of psychiatric diseases. For their clinical deployment, fairness must be evaluated alongside accuracy. Fairness requires predictive models to not unfairly disadvantage specific demographic groups. Failure to assess model fairness prior to use risks perpetuating healthcare inequalities. Despite its importance, empirical
-
The BJPsych: your journal, your voice, your research, your choice Br. J. Psychiatry (IF 10.5) Pub Date : 2023-11-01 Gin S. Malhi
There is a long tradition of excellence in research and clinical expertise in psychiatry across Britain. The BJPsych aims to reflect this wealth of mental science and practical experience alongside the very best of research and clinical practice from around the world using a variety of different kinds of articles.
-
Catching the threads: caregiving in Alzheimer's disease Br. J. Psychiatry (IF 10.5) Pub Date : 2023-11-01 Elizabeth Kuipers
As someone who has researched the effects on carers living with people with severe psychiatric disorders, the author describes her own recent experience of being a carer. The article serves as a companion piece to her psychiatrist husband's account of his cognitive decline in Alzheimer's disease.
-
Artificial intelligence and increasing misinformation Br. J. Psychiatry (IF 10.5) Pub Date : 2023-10-26 Scott Monteith, Tasha Glenn, John R. Geddes, Peter C. Whybrow, Eric Achtyes, Michael Bauer
With the recent advances in artificial intelligence (AI), patients are increasingly exposed to misleading medical information. Generative AI models, including large language models such as ChatGPT, create and modify text, images, audio and video information based on training data. Commercial use of generative AI is expanding rapidly and the public will routinely receive messages created by generative
-
Severe mental illness, race/ethnicity, multimorbidity and mortality following COVID-19 infection: nationally representative cohort study Br. J. Psychiatry (IF 10.5) Pub Date : 2023-10-25 Jayati Das-Munshi, Ioannis Bakolis, Laia Bécares, Jacqueline Dyer, Matthew Hotopf, Josephine Ocloo, Robert Stewart, Ruth Stuart, Alex Dregan
Background The association of COVID-19 with death in people with severe mental illness (SMI), and associations with multimorbidity and ethnicity, are unclear.Aims To determine all-cause mortality in people with SMI following COVID-19 infection, and assess whether excess mortality is affected by multimorbidity or ethnicity.Method This was a retrospective cohort study using primary care data from the
-
Psychological framework to understand interpersonal violence by forensic patients with psychosis Br. J. Psychiatry (IF 10.5) Pub Date : 2023-10-20 Sinéad Lambe, Kate Cooper, Seena Fazel, Daniel Freeman
Background Forensic patients with psychosis often engage in violent behaviour. There has been significant progress in understanding risk factors for violence, but identification of causal mechanisms of violence is limited.Aims To develop a testable psychological framework explaining violence in psychosis – grounded in patient experience – to guide targeted treatment development.Method We conducted
-
Adverse childhood experiences and psychological functioning among women with schizophrenia or bipolar disorder: population-based study Br. J. Psychiatry (IF 10.5) Pub Date : 2023-10-18 Ole Köhler-Forsberg, Fenfen Ge, Arna Hauksdóttir, Edda Bjork Thordardottir, Kristjana Ásbjörnsdóttir, Harpa Rúnarsdóttir, Gunnar Tómasson, Jóhanna Jakobsdóttir, Berglind Guðmundsdóttir, Andri Steinþór Björnsson, Engilbert Sigurðsson, Thor Aspelund, Unnur A. Valdimarsdottir
Background Adverse childhood experiences (ACEs) are well-known risk factors for schizophrenia and bipolar disorder.Aims The aim was to study the associations between specific ACEs and psychological functioning in women with schizophrenia or bipolar disorder.Method Among 29 367 women (mean age 44 years) from the Icelandic Stress-And-Gene-Analysis (SAGA) study, 534 (1.8%, mean age 40) reported having
-
From awareness to action: an urgent call to reduce mortality and improve outcomes in eating disorders Br. J. Psychiatry (IF 10.5) Pub Date : 2023-10-18 Agnes Ayton, Ali Ibrahim, James Downs, Suzanne Baker, Ashish Kumar, Hope Virgo, Gerome Breen
High mortality rates and poor outcomes from eating disorders, especially anorexia nervosa, are largely preventable and require urgent action. A national strategy to address this should include prevention; early detection; timely access to integrated physical and psychological treatments; safe management of emergencies; suicide prevention; and investment in training, services and research.
-
Measuring the impact of therapy on medication use: data-linkage study Br. J. Psychiatry (IF 10.5) Pub Date : 2023-10-18 Julie-Ann Jordan, Adam Elliott, David Mongan, Kevin F. W. Dyer
Background The psychological therapies service (PTS) in the Northern Health and Social Care Trust, in Northern Ireland, provides therapies to adults with moderate or severe mental health difficulties. Psychometric outcomes data are routinely collected to assess if a patient demonstrates significant improvement in their main presenting problem area following therapy. The wider impact of therapy is not
-
The BJPsych: from asylum to psychiatry by dint of mental science Br. J. Psychiatry (IF 10.5) Pub Date : 2023-10-17 Gin S. Malhi
After thanking his predecessors, the newly appointed College Editor and Editor-in-Chief of The British Journal of Psychiatry, Professor Gin Malhi, outlines both the historical and personal significance of the journal in this proemial editorial.
-
Neurocognitive skills and vulnerability for psychosis in depression and across the psychotic spectrum: findings from the PRONIA Consortium Br. J. Psychiatry (IF 10.5) Pub Date : 2023-10-17 Carolina Bonivento, Lana Kambeitz-Ilankovic, Eleonora Maggioni, Stefan Borgwardt, Rebekka Lencer, Eva Meisenzahl, Joseph Kambeitz, Stephan Ruhrmann, Raimo K. R. Salokangas, Alessandro Bertolino, Alexandra Stainton, Julian Wenzel, Christos Pantelis, Stephen J. Wood, Rachel Upthegrove, Nikolaos Koutsouleris, Paolo Brambilla, the PRONIA Consortium
Background Neurocognitive deficits are a core feature of psychosis and depression. Despite commonalities in cognitive alterations, it remains unclear if and how the cognitive deficits in patients at clinical high risk for psychosis (CHR) and those with recent-onset psychosis (ROP) are distinct from those seen in recent-onset depression (ROD).Aims This study was carried out within the European project
-
Latent profiles identified from psychological test data for people convicted of sexual offences in the UK Br. J. Psychiatry (IF 10.5) Pub Date : 2023-10-11 Steven M. Gillespie, Ian A. Elliott
Background One size does not fit all in assessment and intervention for people with convictions for sexual offences. Crime scene indicators and risk-related variables have been used to identify distinct clusters of people with convictions for sexual offences, but there is a need for more robust typologies that identify clusters based on psychologically meaningful risk factors that can be targeted in
-
Decoding anxiety–impulsivity subtypes in preadolescent internalising disorders: findings from the Adolescent Brain Cognitive Development study Br. J. Psychiatry (IF 10.5) Pub Date : 2023-09-21 Huaxin Fan, Zhaowen Liu, Xinran Wu, Gechang Yu, Xinrui Gu, Nanyu Kuang, Kai Zhang, Yu Liu, Tianye Jia, Barbara J. Sahakian, Trevor W. Robbins, Gunter Schumann, Wei Cheng, Jianfeng Feng, Benjamin Becker, Jie Zhang
Background Internalising disorders are highly prevalent emotional dysregulations during preadolescence but clinical decision-making is hampered by high heterogeneity. During this period impulsivity represents a major risk factor for psychopathological trajectories and may act on this heterogeneity given the controversial anxiety–impulsivity relationships. However, how impulsivity contributes to the
-
Impact of the COVID-19 pandemic on self-harm and self-harm/suicide ideation: population-wide data linkage study and time series analysis Br. J. Psychiatry (IF 10.5) Pub Date : 2023-09-21 Euan Neil Paterson, Lisa Kent, Dermot O'Reilly, Denise O'Hagan, Siobhan M. O'Neill, Aideen Maguire
Background The COVID-19 pandemic and associated lockdowns were predicted to have a major impact on suicidal behaviour, including self-harm. However, current studies have produced contradictory findings with limited trend data.Aims Nine years of linked individual-level administrative data were utilised to examine changes in hospital-presenting self-harm and ideation (thoughts of self-harm or suicide)
-
Drug-related deaths among housed and homeless individuals in the UK and the USA: comparative retrospective cohort study Br. J. Psychiatry (IF 10.5) Pub Date : 2023-09-04 Emmert Roberts, Caroline Copeland, Keith Humphreys, Chelsea L. Shover
Background The UK and USA currently report their highest number of drug-related deaths since records began, with higher rates among individuals experiencing homelessness.Aims Given that overdose prevention in homeless populations may require unique strategies, we evaluated whether substances implicated in death differed between (a) housed decedents and those experiencing homelessness and (b) between
-
Telepsychiatry versus face-to-face treatment: systematic review and meta-analysis of randomised controlled trials Br. J. Psychiatry (IF 10.5) Pub Date : 2023-09-01 Katsuhiko Hagi, Shunya Kurokawa, Akihiro Takamiya, Mayu Fujikawa, Shotaro Kinoshita, Mari Iizuka, Shota Furukawa, Yoko Eguchi, Taishiro Kishimoto
Background The COVID-19 pandemic has transformed healthcare significantly and telepsychiatry is now the primary means of treatment in some countries.Aims To compare the efficacy of telepsychiatry and face-to-face treatment.Method A comprehensive meta-analysis comparing telepsychiatry with face-to-face treatment for psychiatric disorders. The primary outcome was the mean change in the standard symptom
-
L'imagination (1833) by Honoré-Victorin Daumier (1808-1879) - Psychiatry in art. Br. J. Psychiatry (IF 10.5) Pub Date : 2023-09-01 Alexander Smith,Michael Liebrenz
-
New guidance for self-harm: an opportunity not to be missed Br. J. Psychiatry (IF 10.5) Pub Date : 2023-08-29 Faraz Mughal, Fiona M. Burton, Harriet Fletcher, Karen Lascelles, Rory C. O'Connor, Sarah Rae, Alex B. Thomson, Nav Kapur
In this editorial we, as members of the 2022 NICE Guideline Committee, highlight and discuss what, in our view, are the key guideline recommendations (generated through evidence synthesis and consensus) for mental health professionals when caring for people after self-harm, and we consider some of the implementation challenges.
-
ICD-11 and bipolar II disorder: so much ado and yet nothing new Br. J. Psychiatry (IF 10.5) Pub Date : 2023-08-01 Gin S. Malhi, Erica Bell, Kamaldeep Bhui
The long-awaited 11th revision of the International Classification of Diseases (ICD-11) makes important advances but simultaneously compromises on some aspects, which may have a negative impact on clinical practice. This editorial illustrates the double-edged nature of some of the changes in ICD-11, focusing on mood disorders and specifically the subtyping of bipolar disorder.
-
Cost-effectiveness analysis of physical activity interventions for people with schizophrenia or bipolar disorder: systematic review Br. J. Psychiatry (IF 10.5) Pub Date : 2023-08-01 Huajie Jin, Oluwafunso Kolawole, Zhengwei Wang
Background Clinical guidelines recommend providing physical activity interventions (PAIs) to people with schizophrenia or bipolar disorder for weight management. However, the cost-effectiveness of PAIs is unknown.Aims To evaluate the availability and methodological quality of economic evaluations of PAIs for people with schizophrenia or bipolar disorder.Method Four databases (MEDLINE, Embase, PsycInfo
-
Crichton Royal Hospital, Dumfries, 1939-2013 - Psychiatry in pictures. Br. J. Psychiatry (IF 10.5) Pub Date : 2023-08-01 R H S Mindham
-
Apropos suicide verdicts: Lord Clifford strangled himself with his cravat in 1673? Beyond reasonable doubt versus the balance of probabilities - Psychiatry in the arts. Br. J. Psychiatry (IF 10.5) Pub Date : 2023-08-01 Greg Wilkinson
-
Jackson Pollock's psychoanalytic drawings - Psychiatry in the arts. Br. J. Psychiatry (IF 10.5) Pub Date : 2023-08-01 Karrish Devan,Yasamine Farahani Englefield
-
Theodor Meynert (1833-1892) - controversies, contributions and cytoarchitectonics - Psychiatry in history. Br. J. Psychiatry (IF 10.5) Pub Date : 2023-08-01 Madhusudan Dalvi
-
Association of cannabis, cannabidiol and synthetic cannabinoid use with mental health in UK adolescents Br. J. Psychiatry (IF 10.5) Pub Date : 2023-07-24 James Hotham, Rebecca Cannings-John, Laurence Moore, Jemma Hawkins, Chris Bonell, Matthew Hickman, Stanley Zammit, Lindsey A. Hines, Linda Adara, Julia Townson, James White
Background Cannabis has been associated with poorer mental health, but little is known of the effect of synthetic cannabinoids or cannabidiol (often referred to as CBD).Aims To investigate associations of cannabis, synthetic cannabinoids and cannabidiol with mental health in adolescence.Method We conducted a cross-sectional analysis with 13- to 14-year-old adolescents across England and Wales in 2019–2020
-
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial Br. J. Psychiatry (IF 10.5) Pub Date : 2023-07-14 Colleen Loo, Nick Glozier, David Barton, Bernhard T. Baune, Natalie T. Mills, Paul Fitzgerald, Paul Glue, Shanthi Sarma, Veronica Galvez-Ortiz, Dusan Hadzi-Pavlovic, Angelo Alonzo, Vanessa Dong, Donel Martin, Stevan Nikolin, Philip B. Mitchell, Michael Berk, Gregory Carter, Maree Hackett, John Leyden, Sean Hood, Andrew A. Somogyi, Kyle Lapidus, Elizabeth Stratton, Kirsten Gainsford, Deepak Garg, Nicollette
Background Prior trials suggest that intravenous racemic ketamine is a highly effective for treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed.Aims To assess the acute efficacy and safety of a 4-week course of subcutaneous racemic ketamine in participants with TRD. Trial registration: ACTRN12616001096448 at www.anzctr.org.au.Method This phase 3, double-blind, randomised
-
A new era for the negative symptoms of schizophrenia Br. J. Psychiatry (IF 10.5) Pub Date : 2023-07-10 Emilio Fernandez-Egea, Armida Mucci, Jimmy Lee, Brian Kirkpatrick
Negative symptoms remain one of the major unmet needs for people with schizophrenia, and the past decade has witnessed a surge in interest in negative symptoms. In this themed issue, we present new concepts of negative symptoms and recent findings on their epidemiology and pathophysiology and on therapeutic options for their management.
-
Negative symptoms in the clinic: we treat what we can describe Br. J. Psychiatry (IF 10.5) Pub Date : 2023-07-10 Brian Kirkpatrick, Lauren Luther, Gregory P. Strauss
Recent research has led to important changes in the concepts and assessment of negative symptoms in schizophrenia. We review current negative symptom concepts and their clinical implications, as well as new methods of assessing these symptoms. These changes hold promise for improving our understanding and treatment of negative symptoms.
-
-
Images of recovery: the shovel - Psychiatry in pictures. Br. J. Psychiatry (IF 10.5) Pub Date : 2023-07-10 Andrea Barbieri
-
Childhood attention-deficit hyperactivity disorder problems and mid-life cardiovascular risk: prospective population cohort study Br. J. Psychiatry (IF 10.5) Pub Date : 2023-07-06 Ajay K. Thapar, Lucy Riglin, Rachel Blakey, Stephan Collishaw, George Davey Smith, Evie Stergiakouli, Kate Tilling, Anita Thapar
Background It is well-known that childhood attention-deficit hyperactivity disorder (ADHD) is associated with later adverse mental health and social outcomes. Patient-based studies suggest that ADHD may be associated with later cardiovascular disease (CVD) but the focus of preventive interventions is unclear. It is unknown whether ADHD leads to established cardiovascular risk factors because so few
-
Brain serotonin 1A receptor binding: relationship to peripheral blood DNA methylation, recent life stress and childhood adversity in unmedicated major depression Br. J. Psychiatry (IF 10.5) Pub Date : 2023-07-03 Hanga Galfalvy, Eileen Shea, Jacqueline de Vegvar, Spiro Pantazatos, Yung-yu Huang, Ainsley K. Burke, M. Elizabeth Sublette, Maria A. Oquendo, Francesca Zanderigo, Jeffrey M. Miller, J. John Mann
Background Childhood and lifetime adversity may reduce brain serotonergic (5-HT) neurotransmission by epigenetic mechanisms.Aims We tested the relationships of childhood adversity and recent stress to serotonin 1A (5-HT1A) receptor genotype, DNA methylation of this gene in peripheral blood monocytes and in vivo 5-HT1A receptor binding potential (BPF) determined by positron emission tomography (PET)
-
Cognitive–behavioural versus cognitive–analytic guided self-help for mild-to-moderate anxiety: a pragmatic, randomised patient preference trial Br. J. Psychiatry (IF 10.5) Pub Date : 2023-07-03 Stephen Kellett, Charlotte Bee, Jess Smithies, Vikki Aadahl, Melanie Simmonds-Buckley, Niall Power, Caroline Duggan-Williams, Neil Fallon, Jaime Delgadillo
Background Guided self-help (GSH) for anxiety is widely implemented in primary care services because of service efficiency gains, but there is also evidence of poor acceptability, low effectiveness and relapse.Aims The aim was to compare preferences for, acceptability and efficacy of cognitive–behavioural guided self-help (CBT-GSH) versus cognitive–analytic guided self-help (CAT-GSH).Method This was
-
The effects of collaborative care versus consultation liaison for anxiety disorders and depression in Denmark: two randomised controlled trials Br. J. Psychiatry (IF 10.5) Pub Date : 2023-07-03 Nadja Kehler Curth, Carsten Hjorthøj, Ursula Brinck-Claussen, Kirstine Bro Jørgensen, Susanne Rosendal, Anders Bo Bojesen, Merete Nordentoft, Lene Falgaard Eplov
Background Collaborative care (CC) and consultation liaison (CL) are two conceptual models aiming to improve mental healthcare in primary care. The effects of these models have not been compared in a Danish setting.Aims To examine the effects of CC versus CL for persons with anxiety and depression in Danish general practices (trial registration: NCT03113175 and NCT03113201).Method Two randomised parallel
-
Real-world effectiveness of pharmacological treatments for bipolar disorder: register-based national cohort study Br. J. Psychiatry (IF 10.5) Pub Date : 2023-07-03 Markku Lähteenvuo, Tapio Paljärvi, Antti Tanskanen, Heidi Taipale, Jari Tiihonen
Background Pharmacological treatment patterns for bipolar disorder have changed during recent years, but for better or worse?Aims To investigate the comparative real-world effectiveness of antipsychotics and mood stabilisers in bipolar disorder.Method Register-based cohort study including all Finnish residents aged 16–65 with a diagnosis of bipolar disorder from in-patient care, specialised out-patient
-
Distinguishing between ICD-11 complex post-traumatic stress disorder and borderline personality disorder: clinical guide and recommendations for future research Br. J. Psychiatry (IF 10.5) Pub Date : 2023-06-29 Thanos Karatzias, Martin Bohus, Mark Shevlin, Philip Hyland, Jonathan I. Bisson, Neil Roberts, Marylène Cloitre
Although complex post-traumatic stress disorder and borderline personality disorder are distinct disorders, there is confusion in clinical practice regarding the similarities between the diagnostic profiles of these conditions. We summarise the differences in the diagnostic criteria that are clinically informative and we illustrate these with case studies to enable diagnostic accuracy in clinical practice
-
Risks and familial coaggregation of death by suicide, accidental death and major psychiatric disorders in first-degree relatives of individuals who died by suicide Br. J. Psychiatry (IF 10.5) Pub Date : 2023-06-23 Shih-Jen Tsai, Chih-Ming Cheng, Wen-Han Chang, Ya-Mei Bai, Ju-Wei Hsu, Kai-Lin Huang, Tung-Ping Su, Tzeng-Ji Chen, Mu-Hong Chen
Background Evidence suggests a familial coaggregation of major psychiatric disorders, including schizophrenia, bipolar disorder, major depression (MDD), autism spectrum disorder (ASD) and attention-deficit hyperactivity disorder (ADHD). Those disorders are further related to suicide and accidental death. However, whether death by suicide may coaggregate with accidental death and major psychiatric disorders
-
Clinical index to quantify the 1-year risk for common postpartum mental disorders at the time of delivery (PMH CAREPLAN): development and internal validation Br. J. Psychiatry (IF 10.5) Pub Date : 2023-06-21 Simone N. Vigod, Natalie Urbach, Andrew Calzavara, Cindy-Lee Dennis, Andrea Gruneir, Brett D. Thombs, Mark Walker, Hilary K. Brown
Background Common postpartum mental health (PMH) disorders such as depression and anxiety are preventable, but determining individual-level risk is difficult.Aims To create and internally validate a clinical risk index for common PMH disorders.Method Using population-based health administrative data in Ontario, Canada, comprising sociodemographic, clinical and health service variables easily collectible
-
Effect of prior pharmacotherapy on remission with sequential bilateral theta-burst versus standard bilateral repetitive transcranial magnetic stimulation in treatment-resistant late-life depression Br. J. Psychiatry (IF 10.5) Pub Date : 2023-06-19 Rafae A. Wathra, Benoit H. Mulsant, Zafiris J. Daskalakis, Jonathan Downar, Shawn M. McClintock, Sean M. Nestor, Tarek K. Rajji, Alisson P. Trevizol, Daniel M. Blumberger
Repetitive transcranial magnetic stimulation (rTMS) is used for treatment of late-life depression. In the FOUR-D study, sequential bilateral theta-burst stimulation (TBS) had comparable remission rates to standard bilateral rTMS. Data were analysed from the FOUR-D trial to compare remission rates between two types of rTMS based on the number and class of prior medication trials. The remission rate
-
Treating negative symptoms of schizophrenia: current approaches and future perspectives Br. J. Psychiatry (IF 10.5) Pub Date : 2023-06-05 Oliver Howes, Paolo Fusar-Poli, Martin Osugo
Negative symptoms are core symptoms of schizophrenia which are common throughout the course of the illness. We outline their functional impact, before reviewing the latest research and guidelines on their assessment and treatment. Finally, we discuss conceptual issues related to measurement of negative symptoms and approaches to address these.
-
Point of care assay for blood aripiprazole concentrations: development, validation and utility Br. J. Psychiatry (IF 10.5) Pub Date : 2023-05-31 Matthew Atkins, David Taylor, Ana Catalan, Neville Desouza, Edward Chesney, Thomas J. Reilly, Irina Baburina, Mary Rose Hilaire, Luiz Dratcu, Robert Harland, Salvatore J. Salamone, Philip McGuire
Background The antipsychotic aripiprazole is often used in the treatment of first-episode psychosis. Measuring aripiprazole blood levels provides an objective measure of treatment adherence, but this currently involves taking a venous blood sample and sending to a laboratory for analysis.Aims To detail the development, validation and utility of a new point of care (POC) test for finger-stick capillary
-
The pathophysiology of negative symptoms of schizophrenia: main hypotheses and open challenges Br. J. Psychiatry (IF 10.5) Pub Date : 2023-05-26 Silvana Galderisi, Stefan Kaiser
Important developments in the conceptualisation and classification of negative symptoms have contributed to refining hypotheses on their pathophysiology. The uptake of recent progress is still only partial and the whole field might make a leap forward once relevant studies fully make use of assessment tools based on current conceptualisations.
-
Effect of 25-hydroxyvitamin D levels on the internalising dimension as a transdiagnostic risk factor: Mendelian randomisation study Br. J. Psychiatry (IF 10.5) Pub Date : 2023-05-19 Julian Konzok, Sebastian-Edgar Baumeister, Thomas W. Winkler, Michael F. Leitzmann, Hansjörg Baurecht
Background Observational studies indicate a relationship between vitamin D (25-hydroxyvitamin D; 25OHD) deficiency and the development of internalising disorders, especially depression. However, causal inference approaches (e.g. Mendelian randomisation) did not confirm this relationship. Findings from biobehavioural research suggests that new insights are revealed when focusing on psychopathological
-
Heroin chic is in? Reflective poem by a core trainee working in child and adolescent mental health services - poem. Br. J. Psychiatry (IF 10.5) Pub Date : 2023-05-19 Clare Georgia Kirk Robinson
-
-
Negative symptoms in children and adolescents with early-onset psychosis and at clinical high-risk for psychosis: systematic review and meta-analysis Br. J. Psychiatry (IF 10.5) Pub Date : 2023-05-17 Gonzalo Salazar de Pablo, Ana Catalan, Julio Vaquerizo Serrano, Borja Pedruzo, Luis Alameda, Veronica Sandroni, Alvaro Armendariz, Victoria Rodriguez, Celso Arango, Carmen Moreno, Johnny Downs, Chris Abbott, Jae Il Shin, Marco Solmi, Paolo Fusar-Poli, Christoph U. Correll
Background Early-onset psychosis (EOP) refers to the development of a first episode of psychosis before 18 years of age. Individuals at clinical high risk for psychosis (CHR-P) include adolescents and young adults, although most evidence has focused on adults. Negative symptoms are important prognostic indicators in psychosis. However, research focusing on children and adolescents is limited. Aims
-
Use of cognitive remediation to treat negative symptoms in schizophrenia: is it time yet? Br. J. Psychiatry (IF 10.5) Pub Date : 2023-05-17 Rafael Penadés, Til Wykes
Cognitive remediation is currently recommended to treat cognitive and functional impairments in patients with schizophrenia. Recently, treatment of negative symptoms has been proposed as a new target for cognitive remediation. Evidence of reductions in negative symptoms has been described in different meta-analyses. However, treating primary negative symptoms is still an open question. Despite some
-
The emergence of primary negative symptoms: relevance of timing? Br. J. Psychiatry (IF 10.5) Pub Date : 2023-05-15 Eric Yu Hai Chen, Stephanie Ming Yin Wong, Christy Lai Ming Hui, Yi Nam Suen, Sherry Kit Wa Chan
Negative symptoms are an important symptom dimension in schizophrenia that are often least responsive to antipsychotic medications. We revisit the current practice of identifying ‘primary’ negative symptoms and suggest that its concept would benefit from a further elaboration of their timing of emergence in relation to the dynamic neurobiological changes to enhance their utility in clinical decision-making
-
SARS-CoV-2 susceptibility and COVID-19 illness course and outcome in people with pre-existing neurodegenerative disorders: systematic review with frequentist and Bayesian meta-analyses Br. J. Psychiatry (IF 10.5) Pub Date : 2023-05-15 Muhannad Smadi, Melina Kaburis, Youval Schnapper, Gabriel Reina, Patricio Molero, Marc L. Molendijk
Background People with neurodegenerative disease and mild cognitive impairment (MCI) may have an elevated risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and may be disproportionally affected by coronavirus disease 2019 (COVID-19) once infected.Aims To review all eligible studies and quantify the strength of associations between various pre-existing neurodegenerative
-
Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study Br. J. Psychiatry (IF 10.5) Pub Date : 2023-04-24 Ebenezer Oloyede, Olubanke Dzahini, Zadro Abolou, Siobhan Gee, Eromona Whiskey, Diksha Malhotra, Masuma Hussain, Ian Osborne, Cecilia Casetta, Philip McGuire, James H. MacCabe, David Taylor
Background To minimise infection during COVID-19, the clozapine haematological monitoring interval was extended from 4-weekly to 12-weekly intervals in South London and Maudsley NHS Foundation Trust.Aims To investigate the impact of this temporary policy change on clinical and safety outcomes.Method All patients who received clozapine treatment with extended (12-weekly) monitoring in a large London
-
The effectiveness of a primary care-based collaborative care model to improve quality of life in people with severe mental illness: PARTNERS2 cluster randomised controlled trial Br. J. Psychiatry (IF 10.5) Pub Date : 2023-04-20 Richard Byng, Siobhan Creanor, Benjamin Jones, Joanne Hosking, Humera Plappert, Sheriden Bevan, Nicky Britten, Michael Clark, Linda Davies, Julia Frost, Linda Gask, Bliss Gibbons, John Gibson, Pollyanna Hardy, Charley Hobson-Merrett, Peter Huxley, Alison Jeffery, Steven Marwaha, Tim Rawcliffe, Siobhan Reilly, Debra Richards, Ruth Sayers, Lynsey Williams, Vanessa Pinfold, Maximillian Birchwood
Background Individuals living with severe mental illness can have significant emotional, physical and social challenges. Collaborative care combines clinical and organisational components. Aims We tested whether a primary care-based collaborative care model (PARTNERS) would improve quality of life for people with diagnoses of schizophrenia, bipolar disorder or other psychoses, compared with usual care
-
The Fairy Tale King and his royal psychiatrist: the contribution to neuroscience of Dr Johann Bernhard Aloys von Gudden, psychiatrist to King Ludwig II - Psychiatry in history. Br. J. Psychiatry (IF 10.5) Pub Date : 2023-05-01 Madhusudan Dalvi
-
The illumination of dreams: André Breton's (1896-1966) Les vases communicants - psychiatry in literature. Br. J. Psychiatry (IF 10.5) Pub Date : 2023-05-01 George Ikkos
-
Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis Br. J. Psychiatry (IF 10.5) Pub Date : 2023-03-30 Korinne Northwood, E. Pearson, U. Arnautovska, S. Kisely, M. Pawar, M. Sharma, K. Vitangcol, E. Wagner, N. Warren, Dan Siskind
Background Although clozapine is the most efficacious medication for treatment-refractory schizophrenia, not all patients will have an adequate response. Optimising clozapine dose using therapeutic drug monitoring could therefore maximise response. Aims Using individual patient data, we undertook a receiver operating characteristic (ROC) curve analysis to determine an optimal therapeutic range for
-
Reflections on Franz Gall and phrenology - Psychiatry in history. Br. J. Psychiatry (IF 10.5) Pub Date : 2023-04-01 Melanie Leilan Marcille,Brent R Carr
-
Authors' reply. RE: Proposed Assisted Dying Bill: implications for mental healthcare and psychiatrists. Br. J. Psychiatry (IF 10.5) Pub Date : 2023-04-01 Gin S Malhi,Kamaldeep Bhui
-
Author's reply. RE: Effectiveness and cost-effectiveness of psychiatric mother and baby units: quasi-experimental study. Br. J. Psychiatry (IF 10.5) Pub Date : 2023-04-01 Kylee Trevillion,Louise M Howard,Sarah Byford,Billie Lever-Taylor